| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7473761 | RECORDATI RARE | Somatostatin analogues |
Dec, 2026
(3 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8822637 | RECORDATI RARE | Somatostatin analogues |
Aug, 2023
(a month ago) | |
| US7759308 | RECORDATI RARE | Microparticles comprising somatostatin analogues |
Oct, 2026
(3 years from now) | |
| US9351923 | RECORDATI RARE | Extended-release composition comprising a somatostatin derivative in microparticles |
May, 2028
(4 years from now) | |
Signifor Lar Kit is owned by Recordati Rare.
Signifor Lar Kit contains Pasireotide Pamoate.
Signifor Lar Kit has a total of 4 drug patents out of which 1 drug patent has expired.
Expired drug patents of Signifor Lar Kit are:
- US8822637
Signifor Lar Kit was authorised for market use on 15 December, 2014.
Signifor Lar Kit is available in for suspension;intramuscular dosage forms.
Signifor Lar Kit can be used as method of treating acromegaly.
The generics of Signifor Lar Kit are possible to be released after 23 May, 2028.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity (ODE) | Jun 29, 2025 |
Drugs and Companies using PASIREOTIDE PAMOATE ingredient
Market Authorisation Date: 15 December, 2014
Treatment: Method of treating acromegaly
Dosage: FOR SUSPENSION;INTRAMUSCULAR
SIGNIFOR LAR KIT family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic